00000nam 2200000zi 4500 9.914730 CaOODSP 20240103094850 m o d f cr mn||||||||| 220823t20222022onc ob f000 0 eng d 9780660451770 CaOODSP eng rda CaOODSP n-cn--- H164-327/2022E-1-PDF Guidance on nitrosamine impurities in medications. Ottawa, ON : Health Canada = Santé Canada, 2022. ©2022 1 online resource (iii, 25 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Cover title. "Date adopted: September 1, 2022. Effective date: September 1, 2022." Issued also in French under title: Lignes directrices sur les impuretés de nitrosamine dans les médicaments. Includes bibliographical references. "Evaluating and managing the risks of N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products"--Cover. Nitrosoamines Risk assessment Canada. Drugs Risk assessment Canada. Biologicals Risk assessment Canada. Radiopharmaceuticals Risk assessment Canada. Pharmaceutical policy Canada. Canada. Health Canada, issuing body. Lignes directrices sur les impuretés de nitrosamine dans les médicaments. (CaOODSP)9.914732 Guidance on nitrosamine impurities in medications. April 17, 2023 (CaOODSP)9.921323 Guidance on nitrosamine impurities in medications. April 2022 (CaOODSP)9.907323 PDF 422 KB https://publications.gc.ca/collections/collection_2022/sc-hc/H164-327-2022-eng-1.pdf 220382